262
Participants
Start Date
February 14, 2018
Primary Completion Date
September 26, 2018
Study Completion Date
September 26, 2018
VP-102 - Cantharidin, Topical Film Forming Solution
VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Up to 4 applications of VP-102 will be administered to Molluscum lesions at 21-day intervals.
Placebo -Topical Film Forming Solution without VP-102
Placebo a single-use drug device combination product containing only the vehicle. Up to 4 applications of Placebo will be administered to Molluscum lesions at 21-day intervals.
The Education and Research Foundation, Lynchburg
Solution Through Advanced Research, Jacksonville
Lenus Research and Medical Group, Sweetwater
Pedia Research, Owensboro
Dermatology Center of Northwestern Indiana, Crown Point
Pedia Research, Evansville
Hamzavi Dermatology, Fort Gratiot
Northwestern Memorial Hospital, Chicago
Midwest Children's Health-Northwoods, Lincoln
Midwest Children's Health, Lincoln
DCOL Center for Clinical Research, Longview
Tekton Research, Austin
Rady Children's Hospital, San Diego
Bakersfield Dermatology, Bakersfield
Redwood Family Dermatology, Santa Rosa
Collaborators (1)
Instat Consulting, Inc.
OTHER
Paidion Research, Inc.
INDUSTRY
Database Integrations, Inc.
INDUSTRY
Verrica Pharmaceuticals Inc.
INDUSTRY